Enhancement of the anti-tumor activity of CEA TCB via combination with checkpoint blockade by PD-L1 and interleukin-2 variant immunocytokine

被引：0
|
作者：
Bacac, Marina
Colombetti, Sara
Fahrni, Linda
Fauti, Tanja
Nicolini, Valeria
Sam, Johannes
Papastogiannidis, Petros
Le Clech, Marine
Miot, Xavier
Waldhauer, Inja
Rommel, Karolin
Gerdes, Christian
Klein, Christian
Umana, Pablo
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-1594
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1594
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade
    Zha, Haoran
    Han, Xiao
    Zhu, Ying
    Yang, Fei
    Li, Yongsheng
    Li, Qijing
    Guo, Bo
    Zhu, Bo
    ONCOIMMUNOLOGY, 2017, 6 (10):
  • [32] A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
    Albu, Diana I.
    Wolf, Benjamin J.
    Qin, Yan
    Wang, Xianzhe
    Ulumben, Amy Daniel
    Su, Mei
    Li, Vivian
    Ding, Eirene
    Gonzalo, Jose Angel
    Kong, Jason
    Jadhav, Ruturaj
    Kuklin, Nelly
    Visintin, Alberto
    Gong, Bing
    Schuetz, Thomas J.
    ONCOIMMUNOLOGY, 2024, 13 (01):
  • [33] Anlotinib combined with the PD-L1 blockade exerts the potent anti-tumor immunity in renal cancer treatment
    Li, Jie
    Cao, Peiyu
    Chen, Yuxin
    Wang, Junqi
    Sun, Xiaolei
    Chen, Renfu
    Wang, Gang
    Hou, Jianquan
    EXPERIMENTAL CELL RESEARCH, 2022, 417 (01)
  • [34] Combination of NK Cells and anti-PD-L1 Ab with ADCC enhances the anti-tumor effects in PD-L1 high cancer cells
    Park, Ji-Eun
    Keam, Bhumsuk
    Park, Ha-ram
    Kim, Soyeon
    Ock, Chan-Young
    Kim, Miso
    Kim, Tae Min
    Kim, Dong-Wan
    Heo, Dae Seog
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [35] PD-L1 CHECKPOINT BLOCKADE USING A SINGLE-CHAIN VARIABLE FRAGMENT TARGETING PD-L1 DELIVERED BY RETROVIRAL REPLICATING VECTOR (TOCA 521) ENHANCES ANTI-TUMOR EFFECT IN CANCER MODELS
    Lin, Amy
    Yagiz, Kader
    Hofacre, Andrew
    Munday, Anthony
    Espinoza, Fernando Lopez
    Mendoza, Daniel
    Burrascano, Cynthia
    Gruber, Harry
    Mitchell, Leah
    Jolly, Douglas
    NEURO-ONCOLOGY, 2018, 20 : 280 - 280
  • [36] Combining CEA-IL2v and FAP-IL2v immunocytokines with PD-L1 checkpoint blockade
    Nicolini, Valeria
    Waldhauer, Lnja
    Freimoser-Grundschober, Anne
    Evers, Stefan
    Saro, Jose
    Bacac, Marina
    Gerdes, Christian
    Umana, Pablo
    Klein, Christian
    CANCER RESEARCH, 2016, 76
  • [37] A novel anti-PD1-IL15 immunocytokine potentiates anti-tumor T cell activity of PD-1 checkpoint inhibition and IL-2R-beta-gamma agonism
    Lu, Dan
    Polonskaya, Zhanna
    Chang, Tzi-Pei
    Martomo, Stella
    Luna, Xenia
    Zhang, Zhikai
    Miyara, Faical
    Patel, Jeedar
    CANCER RESEARCH, 2020, 80 (16)
  • [38] Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin
    Chen, Shaomeng
    Zhou, Xiuman
    Yang, Xin
    Li, Wanqiong
    Li, Shuzhen
    Hu, Zheng
    Ling, Chen
    Shi, Ranran
    Liu, Juan
    Chen, Guanyu
    Song, Nazi
    Jiang, Xianxing
    Sui, Xinghua
    Gao, Yanfeng
    BIOMOLECULES, 2021, 11 (09)
  • [39] Anti-tumor efficacy and PD-L1 expression in the tumor microenvironment after poxvirus-based active immunotherapy and PD-1 blockade.
    Mandl, Stefanie J.
    Foy, Susan P.
    Sennino, Barbara
    dela Cruz, Tracy
    Gordon, Evan
    Kemp, Felicia
    Xavier, Veronica
    Rountree, Ryan B.
    Franzusoff, Alex
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] PD-L1 and VEGF dual blockade enhances anti-tumor effect on brain metastasis in hematogenous metastasis model
    Masuda, Chinami
    Onishi, Shinichi
    Yorozu, Keigo
    Kurasawa, Mitsue
    Morinaga, Mamiko
    Wakita, Daiko
    Sugimoto, Masamichi
    CLINICAL & EXPERIMENTAL METASTASIS, 2024, 41 (06) : 909 - 924
12345